A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions

Immune Thrombocytopenia

Interventions

DRUG

Daratumumab Injection

intravenous daratumumab administration

Trial Locations (1)

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER